undamentalytics Newsletter
Sign in

Verrica Pharmaceuticals Inc. insider trading

Every open-market purchase and sale by Verrica Pharmaceuticals Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $18.2M 11 trades by 5 insiders 3 months later: median +9.2% (+7.1% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders
Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Verrica Pharmaceuticals Inc.’s insiders pay?

From August 14, 2018 to August 18, 2026, 17 insiders reported 40 open-market purchases and 18 sales not made under a pre-set plan in Verrica Pharmaceuticals Inc. Twelve months after each purchase was reported, the shares were −38.6% against the S&P 500 on average (median −26.9%), over 25 purchases with a full year of prices; 16% beat the index. After sales, the shares moved −47.2% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 15, 2018 into $138 by November 2, 2026, −40.7% a year. It held shares 81% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $23,689 (+11.1% a year), and held throughout $30,398 (+14.5%).

$0$10.0k$20.0k$30.0k 201820192020202120222023202420252026 $30.4k$23.7k$138
Copying Verrica Pharmaceuticals Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Verrica Pharmaceuticals Inc.'s insiders from August 15, 2018, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 81% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Manning Paul B Director 13 −27.1% (11) 18% 0 — November 25, 2025
White Ted PRESIDENT AND CEO 4 −46.6% (3) 0% 4 −47.2% (2) August 28, 2024
Hayes Christopher G. CHIEF LEGAL OFFICER 3 −76.5% (1) 0% 4 −47.2% (2) August 28, 2024
Goldenberg Gary Chief Medical Officer 1 — — 4 −47.2% (2) August 28, 2024
Bonaccorso Joe CHIEF COMMERCIAL OFFICER 0 — — 4 −47.2% (2) August 28, 2024
Stalfort John A III Director 3 −1.2% (2) 50% 0 — July 5, 2022
Davis A Brian Chief Financial Officer 2 −44.6% (2) 0% 0 — June 7, 2021
Kirby John J. Interim CFO 2 — — 0 — August 18, 2026
Kohler Terry CHIEF FINANCIAL OFFICER 0 — — 2 — August 28, 2024
Palczuk Linda Chief Operating Officer 2 −2.6% (2) 50% 0 — January 17, 2019
Perceptive Advisors LLC 10% owner 2 −116.2% (2) 0% 0 — December 26, 2023
Rieger Jayson CEO and President 2 — — 0 — August 18, 2026
Zawitz David Chief Operating Officer 2 — — 0 — August 18, 2026
Ballaron Craig Director 1 −7.4% (1) 0% 0 — August 26, 2020
Edelman Joseph 10% owner 1 −115.0% (1) 0% 0 — December 29, 2023
Perceptive Life Sciences Master Fund Ltd 10% owner 1 — — 0 — July 5, 2022
Rosenberg Noah L. CMO 1 — — 0 — August 18, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Verrica Pharmaceuticals Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Verrica Pharmaceuticals Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 6 buying crowds with six months of prices, it averaged −21.3% against the index. After 2 selling crowds, −55.7%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
August 31, 20264 buyingnot yetnot yetnot yet
November 28, 20254 buying−43.6%−48.2%not yet
July 31, 20244 selling−80.5%−100.1%−107.6%
February 29, 20242 buying+54.9%−64.3%−103.2%
July 31, 20234 selling−32.3%−11.3%−9.2%
June 30, 20213 buying+7.1%−28.0%−72.4%
August 31, 20205 buying−4.5%+54.5%−9.3%
January 31, 20193 buying−27.8%−12.4%−0.2%
August 31, 20182 buying−27.2%−29.1%−49.0%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Verrica Pharmaceuticals Inc. · Funds · Politicians